Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow NVS by emailGet an email when NVS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NVS, unsubscribe in one click. Privacy
📣 What NVS Says Is Next
H1 2027 · “Zigakibart is currently being evaluated in the Phase III BEYOND study in adults with IgAN, with readout anticipated in H1 2027.”
Company press release, Jul 21, 2026 · SEC filing
H2 2026 · “Del-desiran is currently being evaluated in the Phase III HARBOR study in DM1, with readout anticipated in H2 2026.”
Company press release, Apr 28, 2026 · SEC filing
in 2026 · “Full study readout and submission for the remaining two subtypes of CINDU expected in 2026.”
Company press release, Feb 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full NVS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.